Systematic Literature Review of Key Outcomes Used to Assess Adjunctive Treatments for Parkinson’s Disease
Objective: Understand key efficacy outcomes used to assess adjunctive treatments to carbidopa/levodopa (CD/LD) for Parkinson’s disease (PD). Background: CD/LD is widely considered the most effective…Preclinical characterization of UCB0022, an oral, brain penetrant, selective, clinical-stage positive allosteric modulator of the dopamine 1 receptor (D1 PAM)
Objective: To characterize the in vitro and in vivo pharmacologic profile of UCB0022 Background: Parkinson’s disease (PD) is a progressive neurodegenerative disease with reductions in…Relative bioavailability of levodopa administered as a subcutaneous infusion with ND0612 versus oral immediate-release levodopa/carbidopa tablets
Objective: To determine the relative bioavailability of levodopa when administered as a subcutaneous (SC) levodopa/carbidopa (LD/CD) infusion with ND0612 versus levodopa derived from oral immediate-release…Vodobatinib, a potent, orally bioavailable brain-penetrating inhibitor of c-Abl as a potential neuroprotective agent for the treatment of Parkinson’s Disease
Objective: To compare and contrast nilotinib and vodobatinib regarding efficacy, brain penetration, and safety. Background: Preclinical evidence suggests that c-Abl is critical for pathogenesis of…Antipsychotic use in Parkinson’s disease: a single center retrospective chart review
Objective: To assess the prevalence of antipsychotic (AP) use in people with Parkinson’s disease (PwP), and identify factors associated with AP prescription and differences in…Comparison of efficacy and safety of adjunct treatments to levodopa in patients with Parkinson’s disease and wearing-off: A network meta-analysis of randomized, double-blind trials
Objective: To determine the rankings for efficacy and tolerability of levodopa adjuncts in patients with Parkinson’s disease (PD) and wearing-off by network meta-analysis. Background: When…Diagnosed and Drug-Treated Prevalence of Essential Tremor in Pediatric Patients: Retrospective Analyses of Two US Healthcare Claims Databases
Objective: Estimate the prevalence of diagnosed and drug-treated essential tremor (ET) in the pediatric population using 2 US healthcare claims databases. Background: An ET diagnosis…Preclinical Characterization of Suvecaltamide for Essential Tremor
Objective: To characterize the in vitro T-type calcium (CaV3) channel target pharmacology and in vivo anti-tremor profile of suvecaltamide (JZP385, CX-8998). Background: CaV3 channels, a…Initial experience with levodopa-entacapone-carbidopa intestinal gel infusion (LECIG) for the management of advanced Parkinson’s disease in Slovenia
Objective: To study the initial experience with levodopa-entacapone-carbidopa intestinal gel infusion (LECIG) in routine clinical practice at two University Medical Centers in Slovenia. Background: The…Statin use and incidence of Parkinson’s disease in women from the French E3N cohort study
Objective: To examine whether incident statin use is associated with lower Parkinson’s disease (PD) incidence while considering the potential for reverse causation. Background: Drug repurposing…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 34
- Next Page »